骨髓增生异常综合征的治疗新策略——表观基因调控  

A new therapeutic strategy in myelodysplasia syndromes： modification of the epigenome

作　　者：崔兴(综述)[1] 徐瑞荣(综述)[1] 王军强(综述)[2] 

机构地区：[1]山东中医药大学附属医院血液科,济南250011 [2]山东中医药大学第二附属医院保健科

出　　处：《白血病．淋巴瘤》2009年第10期633-635,共3页Journal of Leukemia & Lymphoma

摘　　要：表观遗传学是研究不涉及DNA序列变化的、可遗传的基因表达调控方式的一门学科。肿瘤中表观遗传学的改变包括影响基因差异表达的DNA甲基化、组蛋白乙酰化／组蛋白去乙酰化和染色质重塑等几个方面。在骨髓增生异常综合征（MDS）中也能观察到这种表观遗传学改变，这一领域在临床和实验中都有极大的研究价值。重点阐述了表观基因调控在MDS治疗中的进展，主要涉及DNA去甲基化和组蛋白去乙酰化酶抑制剂等药物。The term epigenetics refers to a number of biochemical modifications of chromatin that, without altering the primary sequence of DNA, play a role in genomic regulation and in control of particular gene expression. These modifications involve several kinds, such as DNA methylation, histone code modifications and chromatin remodeling. It is accepted that these modifications is as common in solid tumors as it is in hematologic malignancies such as myelodysplastic syndromes（MDS）. So many specialists suggest that the study of this area is very valuable. The current clinical information regarding different forms of epigenetic therapy in patients with MDS were focused in this review.

关 键 词：骨髓增生异常综合征 表观基因 DNA去甲基化 组蛋白去乙酰化酶抑制剂 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R329.28[医药卫生—内科学]